As of Oct 9, 2026 close
- Market cap
- $215.98M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.81$3.20
- Volume (live)
- -
- Avg. volume (3M)
- 7.54M
Akebia Therapeutics (AKBA) Stock Price & Financial Analysis
Akebia Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.80 - $0.83 |
|---|---|
| 52-Week High | $3.20 |
| 52-Week Low | $0.81 |
| Open | $0.82 |
| Volume (last close) | 6.09M |
| Average Volume (3M) | 7.54M |
| Market Cap | 215.98M |
|---|---|
| Shares Outstanding | 269.60M |
| Price to Sales (P/S) | 1.00 |
| Price to Book (P/B) | 8.78 |
| EV/EBITDA | -7.45 |
| Revenue (TTM) | 219.06M |
|---|---|
| Net Income (TTM) | -29.67M |
| Free Cash Flow (TTM) | 40.17M |
| EPS (TTM) | $-0.11 |
| Profit Margin | -13.54% |
| Operating Margin | -6.02% |
| Return on Equity (ROE) | -118.58% |
| Debt to Equity | 1.98 |
| 50-Day MA | $0.95 |
|---|---|
| 200-Day MA | $1.22 |
| 1-Year Change | −71.81% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Akebia Therapeutics at a Glance
Akebia Therapeutics (AKBA) has a market capitalization of $215.98M. The stock trades at 1.0× sales. Over the trailing twelve months it lost $29.67M on revenue of $219.06M and generated $40.17M of free cash flow. Revenue grew 7.5% year over year.
It holds $155.55M in cash and securities against $49.56M of debt, a net cash position of $105.98M.
Akebia Therapeutics does not currently pay a dividend.
The share price is down 71.8% over the past year. At $0.80 it sits near the bottom of its 52-week range of $0.81 to $3.20, below its 200-day moving average of $1.22.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $3.90, 386.8% above the latest close.
Frequently Asked Questions About Akebia Therapeutics
What is the current stock price for AKBA?
As of the Oct 9, 2026 close, AKBA stock trades at $0.80. The 52-week range is $0.81–$3.20, with a day range of $0.80–$0.83.
What is the P/E ratio for AKBA?
The P/E ratio (Price-to-Earnings) for AKBA is shown in the Key Statistics section. This valuation metric helps compare Akebia Therapeutics, Inc. to industry peers.
Does AKBA pay dividends?
Akebia Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.
What do analysts recommend for AKBA?
Based on 5 analysts, the consensus for AKBA is Buy.
What is the market cap of AKBA?
Akebia Therapeutics's market capitalization is $216.0M, classifying it as a micro-cap company. Akebia Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.